爱尔眼科(300015)：全球眼科龙头优势持续强化

Core Viewpoint - The company is rated "Buy" with a target price of RMB 14.0, highlighting its long-term investment value as a leading global ophthalmic medical service provider [1][4]. Industry Overview - The private ophthalmic medical service market in China has grown to nearly RMB 100 billion, accounting for approximately 40% of the overall ophthalmic medical service market. The demand for ophthalmic treatment is significant due to a large patient base, including over 600 million myopia patients and around 150 million cataract patients [1]. - The overall ophthalmic medical service market in China is projected to reach RMB 223.1 billion by 2024, with a CAGR of 12.8% from 2020 to 2024. The private sector's market share is expected to be 42%, approximately RMB 93.7 billion [1]. Company Performance - The company operates over 900 ophthalmic hospitals/centers globally, making it the largest ophthalmic medical group in the world, with operations in China, Europe, Southeast Asia, and more [2]. - In 2024 and the first half of 2025, the company is expected to achieve outpatient volumes of 16.94 million (+12.1% YoY) and 9.25 million (+16.5% YoY), respectively, with surgical volumes of 1.295 million (+9.4% YoY) and 879,000 (+7.63% YoY) [2]. Strategic Initiatives - The company has implemented the "1+8+N" strategy to enhance its domestic business, aiming to establish a world-class ophthalmic medical center and several regional centers. As of the first half of 2025, the company has 355 domestic hospitals and 240 outpatient departments [3]. - The company's overseas revenue is projected to grow at a CAGR of 17.6% from 2020 to 2024, with a 16.5% YoY increase in the first half of 2025, driven by growth in its European and Southeast Asian subsidiaries [3]. Financial Projections - The company is expected to achieve revenues of RMB 22.8 billion, RMB 25 billion, and RMB 27.3 billion for 2025E, 2026E, and 2027E, respectively, with net profits of RMB 3.8 billion, RMB 4.3 billion, and RMB 4.8 billion [4].